CHEMBIO DIAGNOSTICS, INC.
CEMI evidence brief
What we can confirm
- BioSniper Score:
- 2.7 / 10
- Lead Asset:
- dpp respiratory antigen panel (Preclinical)
What it means
What to watch
Prepared research question
What matters most for CEMI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
dpp respiratory antigen panel (Preclinical)
Next Catalyst
—
Tracking 1 pipeline candidate for CHEMBIO DIAGNOSTICS, INC..
Run CHEMBIO DIAGNOSTICS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CHEMBIO DIAGNOSTICS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Governance
Frequently asked questions
What is CHEMBIO DIAGNOSTICS, INC.'s lead drug candidate?
CHEMBIO DIAGNOSTICS, INC.'s most advanced tracked candidate is dpp respiratory antigen panel (Preclinical) for Respiratory infections.
Who is the CEO of CHEMBIO DIAGNOSTICS, INC.?
To Stockholders is the chief executive officer of CHEMBIO DIAGNOSTICS, INC. (CEMI).
What therapeutic areas does CHEMBIO DIAGNOSTICS, INC. focus on?
CHEMBIO DIAGNOSTICS, INC. develops therapies across Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.